SCCA Clinical Studies: Lung Cancer
ABRAXANE® (Nab-Paclitaxel) for Advanced NSCLC (7755)
A Phase II Study of Weekly ABRAXANE® (Nab-Paclitaxel) for Patients with Advanced NSCLC with EGFR Mutations Following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors
Investigator: Christina Baik; Conditions: Lung Cancer; Status: Recruiting; Study ID: NCT01620190
An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Investigator: Laura Chow, MD; Conditions: Lung Cancer; Status: Recruiting; Study ID: NCT01673867
An Open-Label Randomized Phase III Trial of BMS-936558 Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Investigator: Laura Chow, MD; Conditions: Squamous Cell Non-small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01642004
A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer
Investigator: Shilpen Patel, MD; Conditions: Lung Cancer; Solid Tumors; Status: Recruiting; Study ID: NCT01411098
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Investigator: Scott S. Tykodi, MD, PhD; Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer; Status: Recruiting; Study ID: NCT00729664
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Investigator: Laura Chow, MD; Conditions: Tumors Characterized by Genetic Abnormalities of ALK; Status: Recruiting; Study ID: NCT01283516
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Gemcitabine + Cisplatin or Carboplatin as First-line Treatment for Patients With Stage IIIb or IV Squamous Non-small Cell Lung Cancer (NSCLC)
Investigator: Keith D. Eaton, MD; Conditions: Non-Small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01519804
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab maintenance, Erlotinib, Ipilimumab or monotherapy in First line or in Switch Maintenance in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
Investigator: Laura Q.M. Chow, MD; Conditions: Non-small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01454102
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors
Investigator: Laura Q.M. Chow, MD; Conditions: Malignant Solid Tumor; Status: Closed; Study ID: NCT01567163
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors
Investigator: Laura Q.M. Chow, MD; Conditions: Malignant Solid Tumor; Status: Closed; Study ID: NCT01515306
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors
Investigator: Laura Chow, MD; Conditions: Neoplasms by Site; Status: Recruiting; Study ID: NCT01629758
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Investigator: Renato G. Martins, MD, MPH; Conditions: Non-small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01712217
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations
Investigator: Renato G. Martins, MD; Conditions: Advanced Non-small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01336634
A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib
Investigator: Renato G. Martins, MD; Conditions: Non-Small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01685060
A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Investigator: Renato G. Martins, MD; Conditions: Non-Small Cell Lung Cancer; Status: Recruiting; Study ID: NCT01685138